Brii Bio­sciences stops man­u­fac­tur­ing Covid-19 an­ti­body com­bo, plans to with­draw EUA re­quest

Brii Bio­sciences said it will stop man­u­fac­tur­ing its Covid-19 an­ti­body com­bi­na­tion, sold in Chi­na, and is work­ing to with­draw its emer­gency use au­tho­riza­tion re­quest in the US, which it start­ed in Oc­to­ber 2021.

The Bei­jing and North Car­oli­na biotech com­mer­cial­ly launched the treat­ment in Chi­na last Ju­ly but is now ax­ing the work and re­vert­ing re­sources to oth­er “high-pri­or­i­ty pro­grams,” per a Fri­day up­date. The fo­cus now is name­ly he­pati­tis B vi­ral in­fec­tion, post­par­tum de­pres­sion and ma­jor de­pres­sive dis­or­ders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER